Developer docs
API playgroundTry for free, no card

Search company profiles

Davos Alzheimer's Collaborative

Full company profile

uuid000b5wk

Namestring
Davos Alzheimer's Collaborative
Legal namestring
Davos Alzheimer's Collaborative
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Davos Alzheimer's Collaborative (DAC) is a nonprofit multi-stakeholder partnership founded in 2021 and co-convened by the World Economic Forum and The Global CEO Initiative on Alzheimer's Disease, headquartered in Switzerland with a U.S. 501(c)(3) affiliate in Wayne, Pennsylvania. Its mission is to mount a coordinated global response to Alzheimer's disease by accelerating drug development and preparing healthcare systems to deliver new innovations. DAC organizes its work around three core programs: Global Cohorts (building a one-million-person globally diverse research cohort, with 12 cohorts already linked across Africa, Asia, and South America), Global Clinical Trials (linking 90+ trial sites in North America with European and global partners through a technology platform to reduce time and cost of trials), and Healthcare System Preparedness (implementing early detection and diagnosis programs across 70+ sites in 19 countries and 5 continents using digital cognitive assessments and blood-based biomarkers).

The technology stack combines digital cognitive assessment tools (Linus Health, Cogstate Cognigram, Cognivue Clarity) and blood-based biomarker testing (C2N PrecivityAD) for early detection, supported by a centralized implementation infrastructure including the Early Detection Blueprint and the Brain Health Navigator Toolkit. In February 2026, DAC expanded a collaboration with FINGERS Brain Health Institute on FINGERPRINT, an agentic AI system that integrates multiomic, digital, clinical, and population-level prevention trial data to enable globally representative predictive modeling. Complementary initiatives include The Brain House (a convening platform launched at WEF 2025), the Africa Task Force on Brain Health and its 6x5 Plan (launched November 2025 at a G20 event in Johannesburg), and the 2026 Global South Diversity Strategy with LifeArc, Our Future Health, and the Alzheimer's Disease Data Initiative.

DAC's business model is that of a globally funded nonprofit initiative. Revenue derives from philanthropic donations, grants, and in-kind contributions from pharmaceutical companies (Eli Lilly, Roche, Biogen, Eisai, Otsuka), diagnostics companies (C2N, Linus Health, Cogstate, Cognivue), and institutional funders including TMCity, LifeArc, ADDI, and the Gates Foundation. The organization has stated an aspiration to invest over $700 million over time; the confirmed foundational phase closed at $25 million in 2021, followed by $4.5 million in early detection grants deployed in 2022 and additional multi-million-dollar partnership commitments since. There is no product pricing; DAC coordinates resources, research, and policy work rather than selling goods or services.

Short descriptiontext

Davos Alzheimer's Collaborative is a nonprofit multi-stakeholder partnership that accelerates Alzheimer's drug development and healthcare system preparedness globally by building diverse research cohorts, linking clinical trial networks, and deploying early detection programs across 19 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGeneva, Switzerland
HQ citystring
Geneva
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Alzheimer's research coordination, global clinical trials, healthcare system preparedness, brain health collaboration, diverse research cohorts
Industry2 codes
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAJAOAL
Health Systems Strengthening & Universal Health Coverage (UHC) Partnerships
NAICS code1 code
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Membership Organizations8600
Product category
Alzheimer's Research Coordination and Global Health Collaboration
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Philanthropic Donations and Grants
TypeGrants Donations
Description

DAC operates as a nonprofit initiative funded by private sector, government, and philanthropic contributions. The organization has received support from pharmaceutical companies including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, and others. DAC was launched with a goal to invest over $700 million to accelerate innovation in drug development.

davosalzheimerscollaborative.org
2In-Kind Contributions
TypeProfessional Services
Description

DAC receives invaluable contributions of time and talent from supporters including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, C2N, Cognivue, Linus Health, and Cogstate.

davosalzheimerscollaborative.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The Davos Alzheimer's Collaborative (DAC) is a global multi-stakeholder nonprofit initiative that coordinates worldwide efforts to accelerate Alzheimer's disease research, drug development, and healthcare system preparedness. DAC operates three core programs: Global Cohorts (building diverse research cohorts across underrepresented populations), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (improving early detection and diagnosis). DAC convenes governments, pharmaceutical companies, researchers, and patient organizations to drive evidence-based changes in policy and practice.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3x increase in dementia cases projected by 2050 (to 139 million)
+3 more records
Product overview1 text field

The Davos Alzheimer's Collaborative is a pioneering worldwide initiative to cure Alzheimer's disease and improve brain health, organized around three core programs: Global Cohorts (diversifying genetic data for breakthroughs), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (preparing healthcare systems to deliver innovations). Key initiatives include The Brain House (a global convening platform for brain health policy), the Africa Task Force on Brain Health's 6x5 Plan, and practical tools like the Early Detection Blueprint and Brain Health Navigator Toolkit. The organization serves as a coordinator rather than a product vendor, extending global research into the Global South where the majority of Alzheimer's cases exist.

Product and service7 records
1Global Cohorts
CategoryResearch Program
Description

Global Cohorts is a DAC program that builds diverse research cohorts across underrepresented populations to provide high-quality data as the foundation for identifying new biomarkers and developing targeted Alzheimer's treatments. DAC is working to build a cohort of one million people reflecting the disease in all its global diversity, having linked 12 cohorts spanning Africa, Asia, and South America with 20+ additional cohorts under consideration.

2Global Clinical Trials
CategoryClinical Trials Program
Description

Global Clinical Trials is a DAC program that builds a global clinical trial network and technology platform linking trial sites around the world to reduce the time and cost of Alzheimer's clinical trials, connect researchers worldwide, and accelerate drug development. DAC is linking 90 trial sites in North America with over a dozen in Europe while surveying site capacity to extend future trials globally.

3Healthcare System Preparedness
CategoryHealthcare System Program
Description

Healthcare System Preparedness is a DAC program that invests in healthcare systems and solution providers to improve rates of early, accurate Alzheimer's diagnosis and ensure healthcare systems worldwide are prepared to deliver new innovations. Includes 70 sites across 19 countries and 5 continents with pilot implementations of digital cognitive assessments and blood biomarker testing.

4The Brain House
CategoryConvening Initiative
Description

The Brain House is a global platform hosted by DAC that convenes leaders across healthcare, finance, government, and technology to translate ideas into action on brain health. Hosted at the WEF Annual Meeting in Davos, G7, G20, and UNGA, it positions brain health as a strategic economic priority.

5Africa Task Force on Brain Health (6x5 Plan)
CategoryRegional Initiative
Description

The Africa Task Force on Brain Health is a multi-level, multisectoral coalition uniting experts from Africa's five geopolitical regions through six working groups to accelerate brain health innovation across the continent. The 6x5 Plan is a five-year Brain Health Action Plan launched in 2025 to promote brain health and economic growth across Africa.

6FINGERPRINT AI System Collaboration
CategoryAI/Data Platform
Description

The FINGERPRINT collaboration is an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The system enables globally representative AI modeling by integrating DAC's Global Cohorts data into FINGERPRINT's analytical workflows to support predictive modeling that is biologically, culturally, and environmentally generalizable.

7Brain Health Navigator Program
CategoryPatient Navigation Program
Description

Brain Health Navigator is a DAC program providing resources for patients and providers to support intuitive coordination along the brain-health pathway, spanning frontline patient interactions through diagnosis. Launched at six sites across the U.S.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-06
Description

Partnership to embed diversity as a foundational principle in global dementia research, developing lower-cost diagnostics such as finger-prick blood tests and AI-driven voice analysis tools.

2FINGERS Brain Health Institute (FBHI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Expanded global collaboration to advance AI-driven discovery for Alzheimer's prevention, centered on FINGERPRINT—an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The partnership integrates DAC's Global Cohorts data into FINGERPRINT's analytical workflows to support predictive modeling.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-20
Description

WEF co-convened and co-founded DAC, providing the platform and network to launch this global initiative. WEF continues to serve as a key convening partner, hosting DAC's activities at the WEF Annual Meeting in Davos.

4Global CEO Initiative on Alzheimer's Disease (CEOi)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CEOi co-convened and co-founded DAC alongside WEF. CEOi brings together private sector executives to drive innovation in Alzheimer's research and care.

davosalzheimerscollaborative.org
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partner in the 2026 strategy to diversify data in global dementia research, particularly addressing the gap where 90% of genome-wide association study data comes from European ancestry populations.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Gates-funded initiative partnering with DAC to develop lower-cost diagnostics and accelerate brain health research, particularly in underrepresented Global South populations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration launched to harness AI for brain health across Africa, advancing the Africa Task Force on Brain Health initiatives and the 6x5 Plan for continental brain health innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Launched first Alzheimer's research initiative in East Africa, conducting cohort research study and clinical trial. Partnership addresses lack of diversity in Alzheimer's research and aims to improve care and increase access to treatments throughout Africa.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Released statement of interest to work with DAC on shared mission to accelerate discovery and delivery of precision therapeutic interventions for brain diseases including Alzheimer's. CIRM brings $5.5 billion in funding and more than 150 active stem cell programs.

Strategic tierMajorTypeTechnology or Integration
Description

Provided the PrecivityAD blood-based biomarker test for DAC's early detection pilot sites. This test aids in accurate diagnosis of Alzheimer's disease and reduces need for expensive, hard-to-access advanced tests.

Strategic tierMajorTypeTechnology or Integration
Description

Digital cognitive assessment tool (Core Cognitive Evaluation) provided to DAC pilot sites, reducing need for broad neuropsychological testing. Can be administered via tablet in patient's home.

Strategic tierMajorTypeTechnology or Integration
Description

Provided Cognigram digital cognitive assessment to DAC pilot sites as part of the innovative early detection effort using cutting-edge technology.

Strategic tierMajorTypeTechnology or Integration
Description

Provided Cognivue Clarity digital cognitive assessment to DAC programs, including the Avant Institute grant project for pharmacy-based cognitive screening in rural and underserved communities.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership to link clinical trial sites and accelerate Alzheimer's research. Working with DAC to expand trial networks from North America into Europe and other regions.

15International One Hundred K+ Cohorts Consortium (IHCC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Working with IHCC to build a cohort of one million people reflecting the disease in all its global diversity. DAC has linked 12 cohorts spanning Africa, Asia and South America with more under consideration.

davosalzheimerscollaborative.org
16Catalight
Strategic tierMajorTypeGTM or Marketing Partner
Description

Partner for Brain House 2026. Catalight brings expertise in value-based care for autism and intellectual/developmental disability services, aligning with brain health initiatives.

davosalzheimerscollaborative.org
17EQT Life Sciences
Strategic tierMajorTypeGTM or Marketing Partner
Description

Partner for Brain House 2026, contributing to the global platform advancing brain health, cognitive resilience, and economic growth.

davosalzheimerscollaborative.org
Strategic tierMajorTypeGTM or Marketing Partner
Description

Partner for Brain House 2026, supporting the global initiative to advance brain health as a strategic economic priority.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner for Brain House 2026, contributing to the global platform for brain health innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

WHO serves as technical advisor on DAC's healthcare system preparedness efforts. WHO Director-General Tedros Adhanom Ghebreyesus delivered keynote at Brain House during WEF 2026. WHO was first global organization to recognize Alzheimer's as a global health threat.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Led the U.K. Early Detection Program to transform early detection by integrating digital cognitive tools into routine clinical care through the READ-OUT study with 10 U.K. healthcare systems.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A nonprofit that funds research on Alzheimer's, macular degeneration, and glaucoma. Comparable to DAC as a disease-focused voluntary health organization issuing research grants and convening scientific communities around brain disorders.

TypeDirect peer
Description

An advocacy and policy nonprofit driving national action on Alzheimer's, and parent of CEOi. Comparable to DAC as a multi-stakeholder Alzheimer's advocacy organization with global ambition and pharma/industry ties.

TypeBroad incumbent
Description

The UN's global health authority that serves as DAC's technical advisor and recognized Alzheimer's as a global health threat. Comparable as the convener of international health policy and standards that DAC's healthcare system preparedness programs align with.

4Alzheimer's Association
TypeDirect peer
Description

The largest U.S. nonprofit dedicated to Alzheimer's care, support, and research. Highly comparable as a disease-specific voluntary health organization driving advocacy, research funding, and care system improvements for Alzheimer's patients and families.

TypeDirect peer
Description

A nonprofit that funds translational Alzheimer's drug discovery and diagnostics research globally. Directly comparable to DAC as a funder and convener of Alzheimer's R&D with strong ties to pharmaceutical and biotech sponsors.

TypeOthers
Description

A public-private global health partnership explicitly cited by DAC as the operational archetype for its global coordination mechanism. Comparable as a multi-stakeholder alliance mobilizing large-scale capital and delivery capacity for global health.

TypeDirect peer
Description

A clinical trial network organization that links Alzheimer's trial sites across North America and is a direct DAC partner. Comparable as a clinical-trial-focused infrastructure provider accelerating Alzheimer's drug development.

TypeOthers
Description

A multi-stakeholder global partnership — explicitly cited by Margaret Chan and DAC as the structural model for DAC. Comparable as a global convening and funding mechanism accelerating R&D against a major health threat.

9Global CEO Initiative on Alzheimer's Disease (CEOi)
TypeBroad incumbent
Description

The private-sector coalition that co-founded and convenes DAC, bringing together executives to drive Alzheimer's innovation. Highly comparable as a senior-level multi-stakeholder convening body focused on accelerating Alzheimer's breakthroughs.

TypeDirect peer
Description

A Gates-funded initiative partnering with DAC on data sharing and lower-cost diagnostics for dementia. Directly comparable as a global data and research infrastructure nonprofit targeting Alzheimer's and dementia.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Davos Alzheimer's Collaborative

Alzheimer's Research Coordination and Global Health Collaborationdavosalzheimerscollaborative.org

Davos Alzheimer's Collaborative is a nonprofit multi-stakeholder partnership that accelerates Alzheimer's drug development and healthcare system preparedness globally by building diverse research cohorts, linking clinical trial networks, and deploying early detection programs across 19 countries.

What Davos Alzheimer's Collaborative does

Davos Alzheimer's Collaborative (DAC) is a nonprofit multi-stakeholder partnership founded in 2021 and co-convened by the World Economic Forum and The Global CEO Initiative on Alzheimer's Disease, headquartered in Switzerland with a U.S. 501(c)(3) affiliate in Wayne, Pennsylvania. Its mission is to mount a coordinated global response to Alzheimer's disease by accelerating drug development and preparing healthcare systems to deliver new innovations. DAC organizes its work around three core programs: Global Cohorts (building a one-million-person globally diverse research cohort, with 12 cohorts already linked across Africa, Asia, and South America), Global Clinical Trials (linking 90+ trial sites in North America with European and global partners through a technology platform to reduce time and cost of trials), and Healthcare System Preparedness (implementing early detection and diagnosis programs across 70+ sites in 19 countries and 5 continents using digital cognitive assessments and blood-based biomarkers).

The technology stack combines digital cognitive assessment tools (Linus Health, Cogstate Cognigram, Cognivue Clarity) and blood-based biomarker testing (C2N PrecivityAD) for early detection, supported by a centralized implementation infrastructure including the Early Detection Blueprint and the Brain Health Navigator Toolkit. In February 2026, DAC expanded a collaboration with FINGERS Brain Health Institute on FINGERPRINT, an agentic AI system that integrates multiomic, digital, clinical, and population-level prevention trial data to enable globally representative predictive modeling. Complementary initiatives include The Brain House (a convening platform launched at WEF 2025), the Africa Task Force on Brain Health and its 6x5 Plan (launched November 2025 at a G20 event in Johannesburg), and the 2026 Global South Diversity Strategy with LifeArc, Our Future Health, and the Alzheimer's Disease Data Initiative.

DAC's business model is that of a globally funded nonprofit initiative. Revenue derives from philanthropic donations, grants, and in-kind contributions from pharmaceutical companies (Eli Lilly, Roche, Biogen, Eisai, Otsuka), diagnostics companies (C2N, Linus Health, Cogstate, Cognivue), and institutional funders including TMCity, LifeArc, ADDI, and the Gates Foundation. The organization has stated an aspiration to invest over $700 million over time; the confirmed foundational phase closed at $25 million in 2021, followed by $4.5 million in early detection grants deployed in 2022 and additional multi-million-dollar partnership commitments since. There is no product pricing; DAC coordinates resources, research, and policy work rather than selling goods or services.

Davos Alzheimer's Collaborative firmographics

Firmographics
Name
Davos Alzheimer's Collaborative
Legal name
Davos Alzheimer's Collaborative
Website
https://davosalzheimerscollaborative.org
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Davos Alzheimer's Collaborative is a nonprofit multi-stakeholder partnership that accelerates Alzheimer's drug development and healthcare system preparedness globally by building diverse research cohorts, linking clinical trial networks, and deploying early detection programs across 19 countries.
Ownership category
akta.pro rank

Davos Alzheimer's Collaborative industry classification

Industry
Product category
Alzheimer's Research Coordination and Global Health Collaboration
NAICS
Voluntary Health Organizations (813212)
SIC
Services-Membership Organizations (8600)
akta.pro industry
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAJAOAL
Health Systems Strengthening & Universal Health Coverage (UHC) Partnerships

Keywords

  • Alzheimer's research coordination
  • Global clinical trials
  • Healthcare system preparedness
  • Brain health collaboration
  • Diverse research cohorts

Where Davos Alzheimer's Collaborative is headquartered

Location

Headquarters

HQ city
Geneva
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Davos Alzheimer's Collaborative business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Philanthropic Donations and Grants: DAC operates as a nonprofit initiative funded by private sector, government, and philanthropic contributions. The organization has received support from pharmaceutical companies including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, and others. DAC was launched with a goal to invest over $700 million to accelerate innovation in drug development.
  2. In-Kind Contributions: DAC receives invaluable contributions of time and talent from supporters including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, C2N, Cognivue, Linus Health, and Cogstate.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Davos Alzheimer's Collaborative product offering

Product offering

Core offering

The Davos Alzheimer's Collaborative (DAC) is a global multi-stakeholder nonprofit initiative that coordinates worldwide efforts to accelerate Alzheimer's disease research, drug development, and healthcare system preparedness. DAC operates three core programs: Global Cohorts (building diverse research cohorts across underrepresented populations), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (improving early detection and diagnosis). DAC convenes governments, pharmaceutical companies, researchers, and patient organizations to drive evidence-based changes in policy and practice.

Product overview

The Davos Alzheimer's Collaborative is a pioneering worldwide initiative to cure Alzheimer's disease and improve brain health, organized around three core programs: Global Cohorts (diversifying genetic data for breakthroughs), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (preparing healthcare systems to deliver innovations). Key initiatives include The Brain House (a global convening platform for brain health policy), the Africa Task Force on Brain Health's 6x5 Plan, and practical tools like the Early Detection Blueprint and Brain Health Navigator Toolkit. The organization serves as a coordinator rather than a product vendor, extending global research into the Global South where the majority of Alzheimer's cases exist.

Differentiator

Problem solved

Functional benefit

Products and services

  • Global Cohorts Global Cohorts is a DAC program that builds diverse research cohorts across underrepresented populations to provide high-quality data as the foundation for identifying new biomarkers and developing targeted Alzheimer's treatments. DAC is working to build a cohort of one million people reflecting the disease in all its global diversity, having linked 12 cohorts spanning Africa, Asia, and South America with 20+ additional cohorts under consideration.
  • Global Clinical Trials Global Clinical Trials is a DAC program that builds a global clinical trial network and technology platform linking trial sites around the world to reduce the time and cost of Alzheimer's clinical trials, connect researchers worldwide, and accelerate drug development. DAC is linking 90 trial sites in North America with over a dozen in Europe while surveying site capacity to extend future trials globally.
  • Healthcare System Preparedness Healthcare System Preparedness is a DAC program that invests in healthcare systems and solution providers to improve rates of early, accurate Alzheimer's diagnosis and ensure healthcare systems worldwide are prepared to deliver new innovations. Includes 70 sites across 19 countries and 5 continents with pilot implementations of digital cognitive assessments and blood biomarker testing.
  • The Brain House The Brain House is a global platform hosted by DAC that convenes leaders across healthcare, finance, government, and technology to translate ideas into action on brain health. Hosted at the WEF Annual Meeting in Davos, G7, G20, and UNGA, it positions brain health as a strategic economic priority.
  • Africa Task Force on Brain Health (6x5 Plan) The Africa Task Force on Brain Health is a multi-level, multisectoral coalition uniting experts from Africa's five geopolitical regions through six working groups to accelerate brain health innovation across the continent. The 6x5 Plan is a five-year Brain Health Action Plan launched in 2025 to promote brain health and economic growth across Africa.
  • FINGERPRINT AI System Collaboration The FINGERPRINT collaboration is an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The system enables globally representative AI modeling by integrating DAC's Global Cohorts data into FINGERPRINT's analytical workflows to support predictive modeling that is biologically, culturally, and environmentally generalizable.
  • Brain Health Navigator Program Brain Health Navigator is a DAC program providing resources for patients and providers to support intuitive coordination along the brain-health pathway, spanning frontline patient interactions through diagnosis. Launched at six sites across the U.S.

Quantifiable outcome

  • 3x increase in dementia cases projected by 2050 (to 139 million)
  • +3 more outcomes

Companies that use Davos Alzheimer's Collaborative

Customer profile

Segments5 records

Ideal customer profiles4 records

Davos Alzheimer's Collaborative technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Davos Alzheimer's Collaborative partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered major, core and minor.

  • LifeArcmajorStrategic or Co-development Partner · 6 April 2026Partnership to embed diversity as a foundational principle in global dementia research, developing lower-cost diagnostics such as finger-prick blood tests and AI-driven voice analysis tools.
  • FINGERS Brain Health Institute (FBHI)coreStrategic or Co-development Partner · 23 February 2026Expanded global collaboration to advance AI-driven discovery for Alzheimer's prevention, centered on FINGERPRINT—an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The partnership integrates DAC's Global Cohorts data into FINGERPRINT's analytical workflows to support predictive modeling.
  • World Economic Forum (WEF)coreStrategic or Co-development Partner · 20 January 2021WEF co-convened and co-founded DAC, providing the platform and network to launch this global initiative. WEF continues to serve as a key convening partner, hosting DAC's activities at the WEF Annual Meeting in Davos.
  • Global CEO Initiative on Alzheimer's Disease (CEOi)coreStrategic or Co-development PartnerCEOi co-convened and co-founded DAC alongside WEF. CEOi brings together private sector executives to drive innovation in Alzheimer's research and care.
  • Our Future HealthmajorStrategic or Co-development PartnerPartner in the 2026 strategy to diversify data in global dementia research, particularly addressing the gap where 90% of genome-wide association study data comes from European ancestry populations.
  • Alzheimer's Disease Data InitiativemajorStrategic or Co-development PartnerGates-funded initiative partnering with DAC to develop lower-cost diagnostics and accelerate brain health research, particularly in underrepresented Global South populations.
  • Science for Africa Foundation (SFA Foundation)coreStrategic or Co-development PartnerCollaboration launched to harness AI for brain health across Africa, advancing the Africa Task Force on Brain Health initiatives and the 6x5 Plan for continental brain health innovation.
  • Aga Khan University (Brain and Mind Institute)coreStrategic or Co-development PartnerLaunched first Alzheimer's research initiative in East Africa, conducting cohort research study and clinical trial. Partnership addresses lack of diversity in Alzheimer's research and aims to improve care and increase access to treatments throughout Africa.
  • California Institute for Regenerative Medicine (CIRM)majorStrategic or Co-development PartnerReleased statement of interest to work with DAC on shared mission to accelerate discovery and delivery of precision therapeutic interventions for brain diseases including Alzheimer's. CIRM brings $5.5 billion in funding and more than 150 active stem cell programs.
  • C2N DiagnosticsmajorTechnology or IntegrationProvided the PrecivityAD blood-based biomarker test for DAC's early detection pilot sites. This test aids in accurate diagnosis of Alzheimer's disease and reduces need for expensive, hard-to-access advanced tests.
  • Linus HealthmajorTechnology or IntegrationDigital cognitive assessment tool (Core Cognitive Evaluation) provided to DAC pilot sites, reducing need for broad neuropsychological testing. Can be administered via tablet in patient's home.
  • CogstatemajorTechnology or IntegrationProvided Cognigram digital cognitive assessment to DAC pilot sites as part of the innovative early detection effort using cutting-edge technology.
  • CognivuemajorTechnology or IntegrationProvided Cognivue Clarity digital cognitive assessment to DAC programs, including the Avant Institute grant project for pharmacy-based cognitive screening in rural and underserved communities.
  • Global Alzheimer's PlatformmajorStrategic or Co-development PartnerPartnership to link clinical trial sites and accelerate Alzheimer's research. Working with DAC to expand trial networks from North America into Europe and other regions.
  • International One Hundred K+ Cohorts Consortium (IHCC)coreStrategic or Co-development PartnerWorking with IHCC to build a cohort of one million people reflecting the disease in all its global diversity. DAC has linked 12 cohorts spanning Africa, Asia and South America with more under consideration.
  • CatalightmajorGTM or Marketing PartnerPartner for Brain House 2026. Catalight brings expertise in value-based care for autism and intellectual/developmental disability services, aligning with brain health initiatives.
  • EQT Life SciencesmajorGTM or Marketing PartnerPartner for Brain House 2026, contributing to the global platform advancing brain health, cognitive resilience, and economic growth.
  • LifeArcmajorGTM or Marketing PartnerPartner for Brain House 2026, supporting the global initiative to advance brain health as a strategic economic priority.
  • Wyss CenterminorGTM or Marketing PartnerPartner for Brain House 2026, contributing to the global platform for brain health innovation.
  • World Health Organization (WHO)coreStrategic or Co-development PartnerWHO serves as technical advisor on DAC's healthcare system preparedness efforts. WHO Director-General Tedros Adhanom Ghebreyesus delivered keynote at Brain House during WEF 2026. WHO was first global organization to recognize Alzheimer's as a global health threat.
  • Dementias Platform UKmajorStrategic or Co-development PartnerLed the U.K. Early Detection Program to transform early detection by integrating digital cognitive tools into routine clinical care through the READ-OUT study with 10 U.K. healthcare systems.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Davos Alzheimer's Collaborative competitors and assessment

Company assessment

Direct peers

  • BrightFocus Foundation: A nonprofit that funds research on Alzheimer's, macular degeneration, and glaucoma. Comparable to DAC as a disease-focused voluntary health organization issuing research grants and convening scientific communities around brain disorders.
  • UsAgainstAlzheimer's: An advocacy and policy nonprofit driving national action on Alzheimer's, and parent of CEOi. Comparable to DAC as a multi-stakeholder Alzheimer's advocacy organization with global ambition and pharma/industry ties.
  • Alzheimer's Association: The largest U.S. nonprofit dedicated to Alzheimer's care, support, and research. Highly comparable as a disease-specific voluntary health organization driving advocacy, research funding, and care system improvements for Alzheimer's patients and families.
  • Alzheimer's Drug Discovery Foundation (ADDF): A nonprofit that funds translational Alzheimer's drug discovery and diagnostics research globally. Directly comparable to DAC as a funder and convener of Alzheimer's R&D with strong ties to pharmaceutical and biotech sponsors.
  • Global Alzheimer's Platform Foundation: A clinical trial network organization that links Alzheimer's trial sites across North America and is a direct DAC partner. Comparable as a clinical-trial-focused infrastructure provider accelerating Alzheimer's drug development.
  • Alzheimer's Disease Data Initiative (ADDI): A Gates-funded initiative partnering with DAC on data sharing and lower-cost diagnostics for dementia. Directly comparable as a global data and research infrastructure nonprofit targeting Alzheimer's and dementia.

Broad incumbents

  • World Health Organization (WHO): The UN's global health authority that serves as DAC's technical advisor and recognized Alzheimer's as a global health threat. Comparable as the convener of international health policy and standards that DAC's healthcare system preparedness programs align with.
  • Global CEO Initiative on Alzheimer's Disease (CEOi): The private-sector coalition that co-founded and convenes DAC, bringing together executives to drive Alzheimer's innovation. Highly comparable as a senior-level multi-stakeholder convening body focused on accelerating Alzheimer's breakthroughs.

Others

  • GAVI, the Vaccine Alliance: A public-private global health partnership explicitly cited by DAC as the operational archetype for its global coordination mechanism. Comparable as a multi-stakeholder alliance mobilizing large-scale capital and delivery capacity for global health.
  • CEPI (Coalition for Epidemic Preparedness Innovations): A multi-stakeholder global partnership — explicitly cited by Margaret Chan and DAC as the structural model for DAC. Comparable as a global convening and funding mechanism accelerating R&D against a major health threat.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Davos Alzheimer's Collaborative social profiles

Digital presence

Davos Alzheimer's Collaborative financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Davos Alzheimer's Collaborative leadership team

Management profile

Number of profiles

Profiles8 records

Davos Alzheimer's Collaborative subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Davos Alzheimer's Collaborative funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Davos Alzheimer's Collaborative M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Davos Alzheimer's Collaborative

What does Davos Alzheimer's Collaborative do?

The Davos Alzheimer's Collaborative (DAC) is a global multi-stakeholder nonprofit initiative that coordinates worldwide efforts to accelerate Alzheimer's disease research, drug development, and healthcare system preparedness. DAC operates three core programs: Global Cohorts (building diverse research cohorts across underrepresented populations), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (improving early detection and diagnosis). DAC convenes governments, pharmaceutical companies, researchers, and patient organizations to drive evidence-based changes in policy and practice.

Is Davos Alzheimer's Collaborative a public or private company?

Davos Alzheimer's Collaborative is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Davos Alzheimer's Collaborative founded?

Davos Alzheimer's Collaborative was founded in 2021. It employs 11 to 50 people.

Where is Davos Alzheimer's Collaborative based?

Davos Alzheimer's Collaborative is headquartered in Geneva, Switzerland, in the Europe region.

How does Davos Alzheimer's Collaborative make money?

Two revenue lines are on record. Philanthropic Donations and Grants are the primary driver. The others are in-Kind Contributions.

Who are Davos Alzheimer's Collaborative's main competitors?

Direct peers on record are BrightFocus Foundation, UsAgainstAlzheimer's, Alzheimer's Association, Alzheimer's Drug Discovery Foundation (ADDF), Global Alzheimer's Platform Foundation and Alzheimer's Disease Data Initiative (ADDI). Broad incumbents are World Health Organization (WHO) and Global CEO Initiative on Alzheimer's Disease (CEOi). Others are GAVI, the Vaccine Alliance and CEPI (Coalition for Epidemic Preparedness Innovations).

Does Davos Alzheimer's Collaborative have an API?

No public API is recorded for Davos Alzheimer's Collaborative.

What industry is Davos Alzheimer's Collaborative in?

Davos Alzheimer's Collaborative's product category is Alzheimer's Research Coordination and Global Health Collaboration. Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs), with a secondary code of HLAJAOAL, Health Systems Strengthening & Universal Health Coverage (UHC) Partnerships. Its NAICS code is 813212 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Lab ProductsUK Study Integrates PrecivityAD2 Blood Test for Alzheimer’s in Primary CareResearchers in the United Kingdom are conducting the BEAD-PC study to evaluate C2N Diagnostics' PrecivityAD2 blood test for detecting amyloid plaques in patients with cognitive impairment, integrating it into primary care settings in North West London as part of the Davos Alzheimer's Collaborative's Healthcare System Preparedness program. General practitioners are using the test alongside standard cognitive assessments, with patients showing early signs of impairment referred to the Imperial Memory Unit at Charing Cross Hospital for specialist evaluation. The initiative aims to generate evidence for delivering Alzheimer's diagnostics at scale across the National Health Service by placing diagnostic tools directly within primary care rather than specialist settings.STATCutting-edge dementia research sees the brain as infrastructure | STATJason Karlawish, a professor at the University of Pennsylvania, reports from the 2026 Alzheimer's Association International Conference (AAIC) held at the Excel conference center in London, observing that thinking about the aging brain has transformed over the nine years since his last visit. The article highlights a breakfast meeting convened by the Davos Alzheimer's Collaborative, a 5-year-old organization focused on building an innovation ecosystem to accelerate Alzheimer's breakthroughs and equip healthcare systems. The author argues that breakthroughs in dementia care are creating a new economy of tests, drugs, and risk calculators, representing a shift in how dementia is perceived as an economic and healthcare challenge.GlobeNewswireDavos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and CareThe Davos Alzheimer's Collaborative has congratulated Dr. Andrea Pfeifer on her retirement as CEO of AC Immune, the Swiss biotech company she co-founded in 2003, after 23 years of leadership in neurodegenerative disease research. Pfeifer has played a leading role in defining global clinical development strategies for Alzheimer's and Parkinson's diseases, and remains active through organizations including DAC and the Global CEO Initiative on Alzheimer's Disease. The DAC has expressed confidence that her legacy will influence future neurodegeneration prevention strategies and the broader field of brain health.Health Policy WatchBrain Matters: Equity In The Age Of Cognitive HealthThe Davos Alzheimer's Collaborative announced a new 2026 strategy to embed diversity as a foundational principle in global dementia research, with initiatives spanning Kenya, Chile, Egypt, India, and the broader Global South. The effort addresses a stark data gap — 90% of genome-wide association study data comes from European ancestry populations, while the Global South will account for 80% of dementia cases in the next 20 years — and includes partnerships with LifeArc, Our Future Health, and the Gates-funded Alzheimer's Disease Data Initiative to develop lower-cost diagnostics such as finger-prick blood tests and AI-driven voice analysis tools. Researchers argue that inclusive data collection will not only advance equity but also unlock biological discoveries that benefit populations worldwide.EIN PresswireGlobal Collaboration to Advance AI-Driven Discovery for Alzheimer's Prevention AnnouncedThe Davos Alzheimer's Collaborative (DAC) and the FINGERS Brain Health Institute (FBHI) announced an expanded global collaboration to advance AI-driven discovery for Alzheimer's prevention, centered on FINGERPRINT, an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The partnership aims to enable globally representative AI modeling by integrating DAC's Global Cohorts data, particularly from underrepresented regions in the Global South, into FINGERPRINT's analytical workflows to support predictive modeling that is biologically, culturally, and environmentally generalizable. The collaboration is intended to transform Alzheimer's prevention by connecting global real-world prevention trials with data-driven discovery at scale.BusinessforbrainhealthNine Levers to Build Brain Capital in the WorkplaceUsAgainstAlzheimer's (UsA2), the Davos Alzheimer's Collaborative (DAC), and the McKinsey Health Institute (MHI) partnered to develop a unified framework for workplace brain health, identifying nine cross-cutting risk and resilience factors across mental health, neurological health, and workplace performance domains.EIN PresswireFIVE-YEAR BRAIN HEALTH ACTION PLAN TO POWER ECONOMIC GROWTH LAUNCHED ACROSS AFRICAThe Davos Alzheimer's Collaborative and the Science for Africa Foundation launched Africa's first-ever five-year Brain Health Plan at a G20 side event in Johannesburg, South Africa, creating a continent-wide roadmap to invest in brain capital and strengthen the workforce as an economic growth driver. The plan, developed by a coalition including WHO AFRO, Africa CDC, Aga Khan University, and the University of the Witwatersrand, sets strategic goals across six areas including advocacy, brain economy, and digital/AI. McKinsey Health Institute estimates that scaling brain health interventions globally could add $6.2 trillion annually to world GDP by 2050, while dementia cases in Africa are projected to triple by 2050.BusinessforbrainhealthInternational Markets: Global Brain Health Challenges and StrategiesGlobal leaders from government, academia, and industry convened at a Davos Alzheimer\'s Collaborative session to address brain health as both an economic and public health priority, noting that mental and neurological disorders cost the world economy roughly $3.5 trillion annually. Regional stakeholders are moving from discussion to implementation: India is piloting government-funded brain health clinics in 16 districts, Kenya\'s Aga Khan University is launching a five-year data harmonization program across Africa, Argentina\'s National Congress is deliberating brain health legislation, Europe is pooling €500 million for a Partnership for Brain Health launching in January 2026, and Canada is finalizing a national roadmap ahead of a G7 Summit in Calgary. The session also emphasized the need for ethical guardrails on AI in brain research while warning that climate-related stressors pose an escalating threat to brain development in vulnerable regions.DavosalzheimerscollaborativeDavos Alzheimer's Collaborative launches innovative brain health navigator program for intuitive coordination between patients and providersThe Davos Alzheimer’s Collaborative launched the Brain Health Navigator program to improve coordination between patients and providers for early Alzheimer's diagnosis across six U.S. pilot sites. Eisai Inc., a funder of the initiative, emphasized that timely diagnosis requires collaboration to transform brain health care journeys.GlobeNewswireDavos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North AfricaPacBio was selected as a technology partner for the North African Dementia Registry, a DAC-led project with AUC and UCL. The registry will use PacBio's long-read sequencing to generate multi-omics data on Alzheimer's genetics in North Africa. Data will be accessible via the Alzheimer's Disease Data Initiative platform.